(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) and rink amide resin were purchased from ChemImpex. All solvents were used as received; N-methyl-2-pyrrolidinone (NMP) was purchased from Advanced ChemTech, diisopropylethylamine (DIEA) from Fisher, dimethylsulfoxide (DMSO) from EMD and piperidine from Sigma-Aldrich. PEG 4 -NHS was purchased from Thermo Scientific. Thrombin and chymotrypsin from human pancreas were purchased from Calbiochem. Thromboplastin from rabbit brain was purchased from Sigma-Aldrich. Endoproteinase Glu-C was purchased from Worthington Biochemical Corporation. Fibrinogen-deficient plasma was purchased from Affinity Biologicals.
III. General experimental

Peptide synthesis and purification
Peptide synthesis was performed using standard solid-phase Fmoc chemistry 1,2 on rink amide resin (0.1 mmol) as illustrated in Scheme 1.
Deprotection reaction
Fmoc deprotection was carried out using a 6 mL solution of 20 vol% piperidine in NMP incubated for at least 10 min at rt. The resin is then washed 4 times with 4 mL NMP.
Coupling reaction
The Fmoc amino acid (0.5 mmol) and HBTU (0.5 mmol) were dissolved in 4 mL of NMP containing DIEA (300 mM). This solution was added to rink amide resin (0.1 mmol) in a 12 mL cartridge and the mixture was shaken for at least 30 min at rt. The reaction was determined to be complete based on the Kaiser test. 3 The resin is then washed 4 times with 4 mL NMP. The resin is then washed 4 times with 4 mL NMP.
Cleavage reaction
The peptides were cleaved from the resin using a 5 mL solution of 95 vol% trifluoroacetic acid, 2.5 vol% H 2 O, 2.5 vol% triisopropylsilane incubated for at least 2 h at rt.
Purification
Compounds 1-3 were subjected to rotary evaporation with 5 mL toluene to remove cleavage solution. Fractions containing the product were pooled and lyophilized.
Preparation of 200 mM PBS buffer
Na 2 HPO 4 (0.1 mol), KH 2 PO 4 (0.1 mol), KCl (5.4 mmol) and NaCl (0.274 mol) were added to 900 mL of H 2 O. The solution was adjusted (using either HCl or NaOH) to pH 7.2 and diluted to 1000 mL with H 2 O.
Heat/cool procedure for gel formation
For gel screening, a 4 mL vial was charged with the compound (3-5 mg) and DMSO (0.10 mL) to generate a homogeneous solution. To this solution, 10 mM PBS (0.9 mL) buffer was added, resulting in a white suspension. The suspension was then heated until a homogeneous solution was obtained and allowed to cool to rt. Gels were identified by vial inversion. The sample was diluted by adding 10/90 DMSO/buffer solution (0.10 mL) and retested for gelation. Dilutions were continued until the gel was no longer stable to inversion. The last concentration to give a stable gel was recorded as the critical gelation concentration (cgc).
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Enzymatic gelation assay
Compounds 4-6 were dissolved in DMSO to ~ 60 mM. An aliquot (30 µL) of this solution was added to a 2 mL glass vial. To the vial was also added DMSO (10 µL) and H 2 O (150 µL). 
Atomic force microscopy
Samples were imaged in air using a Dimension Icon AFM (Veeco). Samples were drop-cast and airdried on a glass slide, then imaged in tapping mode using silicon cantilevers (VistaProbes T300R, tip radius <10 nm, force constant 40 N/m, resonance frequency 300 kHz; nanoScience Instruments).
Images were acquired from 2-3 locations in each sample.
Analytical HPLC-MS
Compound was dissolved in 50 vol% CH 3 CN in H 2 O to 2 mg/mL. An aliquot (10 µL) was injected into a Waters © Xbridge C18 column (2.1 x 100 mm) and eluted using a linear gradient of CH 3 CN (5-95%) in 
Experimental
Compound 4 (4.4 mM) was dissolved in 100 mM PBS at pH 7.2 with 10 vol% DMSO. Different concentrations of thrombin were then added and the solutions were monitored for gelation by vial inversion. The time required for a stable gel is recorded in Table S3 .
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IX. Gelation of blood plasma
Experimental Fibrinogen-deficient plasma (270 µL) containing 59 nM thrombin was added to a vial containing 58.8 mM compound 4 (30 µL) or DMSO (30 µL) and was monitored over time for gelation. The plasma containing both thrombin and compound 4 was stable to inversion after a 30-min incubation at rt. No gelation was detected in the other vials after 24 h. Figure S16 . Inversion of vials containing fibrinogen-deficient plasma treated with thrombin and compound 4. The photo was taken after 20 h incubation.
Experimental Fibrinogen-deficient plasma (100 µL) containing compound 4 (12 mM) or DMSO (30 µL) was treated with thromboplastin in 20 mM CaCl 2 (170 µL) or 20 mM CaCl 2 only and was monitored over time for gelation. The plasma containing both thromboplastin and peptide was stable to inversion after a 2 h incubation at rt. Gelation was also detected in the vial containing 20 mM CaCl 2 after 20 h. Figure S17 . Inversion of vials containing fibrinogen-deficient plasma treated with thromboplastin and compound 4. The photo was taken after 20 h incubation.
